PRINCETON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company announced today that Elliott Sigal, M.D., Ph.D., senior vice president, Global Clinical and Pharmaceutical Development, will serve as acting president of the company’s Pharmaceutical Research Institute (PRI). James B.D. Palmer, M.D., F.R.C.P., chief scientific officer and president of the PRI, recently underwent surgery.
Dr. Sigal has been a member of the company’s Executive Committee since May 2001, and for the last several years has led the Global Clinical and Pharmaceutical Development arm of the PRI, working closely with Dr. Palmer. Dr. Sigal will direct the efforts of the global research and development organization, with a focus on development of new medicines and advancing the pipeline. Dr. Sigal began his career with the company in 1997 as a vice president within Drug Discovery. An expert in genomics, Dr. Sigal built the company’s capability and expertise in the application of pharmacogenomics to drug discovery and development.
Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Bristol-Myers Squibb Company
CONTACT: Media - Robert Hutchison, +1-609-252-3901; or Investors - JohnElicker, +1-212-546-3775, both of Bristol-Myers Squibb Company
Web site: http://www.bms.com/
